<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(9)</volume><submitter>Langer C</submitter><funding>Open Access Publication Fund of the University of Freiburg</funding><pubmed_abstract>Adrenocortical carcinoma (ACC) is a heterogeneous malignancy related to poor prognosis and limited treatment options. The orphan drug mitotane (MT) is still a cornerstone in ACC therapy, however, its application is characterized by low aqueous solubility, poor bioavailability, and unfavorable pharmacokinetics, often resulting in below-target plasma concentrations or toxic side effects. Throughout the last decades, nanoparticulate formulations have become attractive carriers to improve anticancer therapy. In this study, injectable MT liposomes (DOPC-MT) and albumin-stabilized MT nanoparticles (BSA-MT) were investigated in depth with respect to their physicochemical properties, and their colloidal and therapeutical stability upon storage. Furthermore, in vitro cytotoxicity was evaluated usin</pubmed_abstract><journal>Pharmaceutics</journal><pagination>1891</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9501383</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids.</pubmed_title><pmcid>PMC9501383</pmcid><pubmed_authors>Hantel C</pubmed_authors><pubmed_authors>Koll-Weber M</pubmed_authors><pubmed_authors>Holzer M</pubmed_authors><pubmed_authors>Langer C</pubmed_authors><pubmed_authors>Suss R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids.</name><description>Adrenocortical carcinoma (ACC) is a heterogeneous malignancy related to poor prognosis and limited treatment options. The orphan drug mitotane (MT) is still a cornerstone in ACC therapy, however, its application is characterized by low aqueous solubility, poor bioavailability, and unfavorable pharmacokinetics, often resulting in below-target plasma concentrations or toxic side effects. Throughout the last decades, nanoparticulate formulations have become attractive carriers to improve anticancer therapy. In this study, injectable MT liposomes (DOPC-MT) and albumin-stabilized MT nanoparticles (BSA-MT) were investigated in depth with respect to their physicochemical properties, and their colloidal and therapeutical stability upon storage. Furthermore, in vitro cytotoxicity was evaluated usin</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-04-08T11:53:15.093Z</modification><creation>2024-11-12T17:40:59.378Z</creation></dates><accession>S-EPMC9501383</accession><cross_references><pubmed>36145639</pubmed><doi>10.3390/pharmaceutics14091891</doi></cross_references></HashMap>